Sartorius Stedim Biotech SA/  FR0013154002  /

Euronext - Paris
7/15/2024  5:37:14 PM Chg. -0.55 Volume Bid5:40:00 PM Ask5:40:00 PM Market Capitalization Dividend Y. P/E Ratio
167.75EUR -0.33% 89,234
Turnover: 14.91 mill.
166.40Bid Size: 100 168.00Ask Size: 200 15.46 bill.EUR 0.41% 49.93

Business description

Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach.
 

Management board & Supervisory board

CEO
Dr. Joachim Kreuzburg
Management board
Alexandra Gatzemeyer, Dr. René Fáber
Supervisory board
Joachim Kreuzburg, René Fáber, Pascale Boissel, Susan Dexter, Romaine Fernandes, Anne-Marie Graffin, Lothar Kappich, Henri Riey
 

Company data

Name: Sartorius Stedim Biotech SA
Address: Avenue de Jouques - CS 91051,F-13781 Aubagne Cedex
Phone: +33-442-84-5600
Fax: +33-442-84-5619
E-mail: info@sartorius-stedim.com
Internet: https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 26.20%
IPO date: -

Investor relations

Name: Petra Kirchhoff
IR phone: +49-551-308-1686
IR Fax: -
IR e-mail: petra.kirchhoff@sartorius.com

Company calendar

CW 29 | 7/19/2024 Interim Report 2nd Quarter/6 Months
CW 42 | 10/17/2024 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Sartorius AG
 
73.60%
free float
 
26.40%